ARA-290 Research Guide 2026

Research Guide, Scientific Context, Mechanism, and Current Research

Definition: ARA-290, also known as cibinetide, is an 11-amino-acid peptide engineered from the helix B surface region of erythropoietin. In the published literature, it is primarily studied for innate repair receptor signaling, inflammatory modulation, small fiber neuropathy research, tissue protection, and repair-related biology.

Research Use Only: This page is provided for educational and research reference purposes only. ARA-290 is not approved by Health Canada or the U.S. FDA as an established therapeutic product for general clinical use, and no medical claims are being made on this page. Current discussion of ARA-290 should remain within a research-only and evidence-based framework.

Key Takeaways

ARA-290, or cibinetide, is an 11-amino-acid peptide derived from the tissue-protective region of erythropoietin.
It is designed to act on the innate repair receptor, often described as a receptor complex involving EPOR and CD131, rather than the classical erythropoietic pathway.
Published research has focused on small fiber neuropathy, inflammatory signaling, tissue protection, and nerve-fiber regeneration markers.
Early human studies in sarcoidosis-associated small fiber neuropathy and type 2 diabetes with neuropathic symptoms reported promising signals, but the evidence base is still limited and not definitive.
A careful research guide should present ARA-290 as an experimental peptide with mechanistic and early clinical interest, not as a proven intervention.

What Is ARA-290?

ARA-290 is a synthetic peptide designed from the three-dimensional tissue-protective domain of erythropoietin, specifically the helix B surface region. Unlike erythropoietin itself, which is associated with red blood cell production, ARA-290 was engineered to selectively activate tissue-protective and repair-oriented signaling without stimulating erythropoiesis in the same way. This distinction is central to how ARA-290 is described in the literature.

Public chemistry references identify cibinetide as PubChem CID 91810664, with commonly cited synonyms including ARA 290, ARA-290, and PHBSP. Guide to Pharmacology also lists its CAS Registry No. 1208243-50-8 in the WHO INN record.

Within the literature, ARA-290 is most often discussed in connection with:

small fiber neuropathy research
inflammatory signaling and tissue repair
corneal nerve fiber abundance
metabolic and neuropathic symptom studies
retinal and organ-protection research models

ARA-290 30-Second Summary

ARA-290 is a research peptide derived from erythropoietin’s tissue-protective domain. Scientists study it because it appears to engage repair-related signaling pathways linked to inflammation control, nerve-fiber health, and tissue recovery, while avoiding the red-blood-cell-stimulating effects that limit erythropoietin’s broader use. The science is promising, especially in neuropathy-related research, but the current evidence base is still early and should not be overstated.

What Researchers Are Studying ARA-290 For

Small Fiber Neuropathy

One of the main areas of interest is small fiber neuropathy, especially in sarcoidosis-associated nerve-fiber loss. In a randomized pilot study, ARA-290 was associated with improvement in small fiber neuropathy symptom scores and showed an acceptable safety profile in that trial population.

A later dose-ranging study reported that cibinetide significantly increased small nerve fiber abundance in the cornea and skin, findings the authors described as consistent with a disease-modifying effect in neuropathy research settings.

Neuropathic Symptom Research in Type 2 Diabetes

In a 2015 phase 2 study, ARA-290 was investigated in people with type 2 diabetes and painful neuropathic symptoms. The authors reported improvements in neuropathic symptom measures and observed changes in corneal nerve fiber density in a subgroup with reduced baseline nerve fiber abundance.

Inflammatory Modulation and Tissue Repair

Review literature on ARA-290 and the innate repair receptor describes the peptide as part of a broader effort to reprogram tissue-damaging inflammatory environments toward repair and healing. This is one of the central ideas behind the compound’s mechanism-oriented scientific interest.

Ocular and Retinal Research

ARA-290 has also been investigated in ocular settings, including diabetic macular edema and corneal nerve-fiber outcomes. This does not establish clinical utility, but it shows the breadth of current research interest around tissue-protective signaling in metabolically stressed tissues.

Organ Protection and Experimental Injury Models

Preclinical studies and reviews have explored ARA-290 in models involving nephrotoxicity, inflammatory injury, neuropathic pain, and ischemic tissue stress. These findings are mechanistic and experimental, but they help explain why ARA-290 is often discussed as a repair-oriented peptide rather than a simple analgesic or growth factor mimic.

Key Research Benefits

1. Small Fiber Neuropathy (SFN)

ARA-290 is a leading candidate in neuropathy research. Clinical trials have demonstrated:

Increased Nerve Density: Significant increases in corneal nerve fiber density (CNFD) and skin nerve fiber abundance.
Pain Reduction: Marked reduction in neuropathic pain symptoms as assessed by the PainDetect and SFNSL scales.
Quality of Life: Improvement in physical functioning dimensions in patients with sarcoidosis-associated neuropathy.

2. Cardiovascular & Metabolic Health

Newer research (2023–2026) has expanded ARA-290’s profile into metabolic and heart health:

Cardiac Resilience: Chronic treatment in research models shows a reduction in age-related cardiac inflammation and preservation of systolic function.
Metabolic Control: Improvements in HbA1c levels and lipid profiles have been observed in type 2 diabetes research models.

3. Renal and Tissue Protection

Ischemia-Reperfusion Injury: ARA-290 has been shown to protect kidneys during transplantation by reducing inflammation immediately post-reperfusion.
Anti-Apoptotic Effects: It shields cells from damage caused by toxins or chemotherapeutic agents like cisplatin.

ARA-290 vs. Erythropoietin (EPO)

Feature	ARA-290 (Cibinetide)	Erythropoietin (EPO)
Size	11 Amino Acids (Small Peptide)	165 Amino Acids (Glycoprotein)
Blood Production	None (Non-hematopoietic)	High (Stimulates RBCs)
Target Receptor	Innate Repair Receptor (IRR)	EPO Receptor (EPOR)
Primary Risk	None significant in trials	Blood clots / High Viscosity
Research Focus	Neuropathy, Inflammation	Anemia, Performance

How ARA-290 May Work

1) Innate Repair Receptor Signaling

The defining mechanistic feature of ARA-290 is its proposed selective interaction with the innate repair receptor, often described as a heteromeric complex involving EPOR and CD131. This receptor system is associated with cytoprotection, inflammation control, and tissue repair rather than classical erythropoiesis.

2) Inflammatory Modulation

Published work suggests that ARA-290 may reduce tissue-damaging inflammatory signaling. In neuropathy research, this has been discussed as one reason the peptide may improve symptoms without acting like a conventional painkiller.

3) Nerve Fiber Repair and Regrowth-Related Biology

Some of the most discussed clinical findings involve corneal nerve fiber density and abundance, as well as related skin-fiber markers. This has made ARA-290 particularly interesting in research on structural nerve-fiber recovery, not just symptom change.

4) Tissue Protection Without Classical Erythropoietic Activity

A major reason ARA-290 was developed is that erythropoietin’s tissue-protective biology has scientific appeal, but its hematopoietic effects create limitations. ARA-290 was engineered to capture part of the protective signaling profile while reducing the red-blood-cell-stimulating component.

Simple Explanation

Think of ARA-290 as a repair-signaling peptide modeled from erythropoietin, but stripped down so researchers can study tissue protection and inflammatory control without leaning on the red-blood-cell effects erythropoietin is known for. The main scientific question is whether that selective signaling can support better outcomes in nerve, retinal, kidney, and other tissue-stress models.

Scientific Context

ARA-290 sits in a distinctive category of research peptides because it is not usually framed as a typical bodybuilding, cosmetic, or metabolic peptide. Its literature is centered on innate repair biology, especially the idea that tissue injury activates protective pathways that can be pharmacologically supported.

That gives ARA-290 a different scientific profile from many other peptides in the broader market. It is more accurately understood as a tissue-protective signaling peptide derived from erythropoietin biology than as a general performance compound. In the current literature, its most serious research context is neuropathy and tissue-repair biology.

ARA-290 Research Summary

What the literature suggests

ARA-290 may improve symptom measures in some small fiber neuropathy research settings.
ARA-290 may increase corneal and skin small nerve fiber abundance in specific study populations.
ARA-290 appears to act through repair-oriented receptor signaling rather than classical erythropoiesis.
Preclinical studies support ongoing interest in anti-inflammatory, neuroprotective, and tissue-protective effects.
Human evidence remains early and limited, so strong clinical conclusions are not justified.

Why ARA-290 Matters in Current Research Discussions

ARA-290 matters because it represents a targeted attempt to isolate tissue-protective signaling from erythropoietin biology without carrying forward the full hematopoietic profile of EPO itself. This has made it relevant in scientific discussions around:

small fiber neuropathy
chronic inflammatory tissue injury
corneal nerve-fiber biomarkers
diabetic tissue-stress models
repair-oriented receptor pharmacology

For research-focused audiences, ARA-290 is compelling because it is tied to a recognizable biological framework rather than vague peptide hype.

ARA-290 vs Erythropoietin

ARA-290 is best understood in contrast to erythropoietin itself.

Erythropoietin

Erythropoietin is well known for stimulating red blood cell production through classical erythropoietic signaling.

ARA-290

ARA-290 was designed to mimic the tissue-protective domain of erythropoietin while selectively engaging repair-oriented biology rather than classical hematopoiesis. That is the conceptual reason it has been explored as a nonerythropoietic peptide for tissue protection and neuropathy research.

This distinction is one of the most important pieces of context for anyone reading about ARA-290.

Limitations of the ARA-290 Literature

The human literature is still relatively limited and concentrated in specific research groups and indications.
Much of the strongest mechanistic enthusiasm comes from a combination of early clinical findings and supportive preclinical work, not large definitive outcome trials.
Corneal nerve fiber and biomarker improvements are scientifically interesting, but they should not be overstated as proof of broad clinical benefit.
ARA-290 should not be presented as an approved or established medical treatment based on the current evidence base.

Research Use and Quality Considerations

ARA-290 is best presented as a research peptide studied in experimental and early clinical contexts involving neuropathy, inflammatory modulation, and tissue-protective biology. For a page like this, the most relevant quality and trust signals are:

verified identity
purity standards
batch-level transparency
proper storage and handling
conservative, evidence-based language
clear separation between published research and unproven claims

Relevant Luxara Labs educational and transparency pages include:

Peptides in Canada Overview
https://luxaralabs.com/peptides-canada/

Knowledge Hub
https://luxaralabs.com/peptides-canada-knowledge-hub/

Luxara Labs Research Index
https://luxaralabs.com/luxara-labs-research-index/

Research Standards & Methodology
https://luxaralabs.com/research-standards-methodology/

Purity Standards
https://luxaralabs.com/peptide-purity-standards-canada/

Quality Standard
https://luxaralabs.com/quality-standard/

Transparency Hub
https://luxaralabs.com/transparency/

How to Read a COA
https://luxaralabs.com/how-to-read-a-coa/

Lab Results
https://luxaralabs.com/lab-results/

Research Use Regulations Canada
https://luxaralabs.com/research-use-regulations-canada/

Peptide Storage and Handling
https://luxaralabs.com/peptide-storage-handling-stability/

Peptides 101
https://luxaralabs.com/peptides101/

Peptide Half Life Explained
https://luxaralabs.com/peptide-half-life-explained/

Related Research Guides

Cerebrolysin Research Guide
https://luxaralabs.com/cerebrolysin-research-canada/

Pinealon Research Guide
https://luxaralabs.com/pinealon-research-guide/

Semax Research Guide
https://luxaralabs.com/semax-canada/

Selank Research Guide
https://luxaralabs.com/selank-canada/

DSIP Research Review
https://luxaralabs.com/dsip-research-review-canada/

Epitalon Research Guide
https://luxaralabs.com/epitalon-canada/

These are not identical compounds, but they help contextualize ARA-290 within the broader research landscape of CNS-adjacent and repair-oriented peptide discussions.

FAQ

What is ARA-290?

ARA-290, also known as cibinetide, is an 11-amino-acid peptide engineered from the tissue-protective helix B surface region of erythropoietin.

What is ARA-290 being researched for?

It is mainly being studied in connection with small fiber neuropathy, inflammatory signaling, tissue repair, corneal nerve-fiber changes, and related protective biology.

Is ARA-290 the same as cibinetide?

Yes. Cibinetide is the commonly used nonproprietary name associated with ARA-290.

What is ARA-290’s CAS number?

Guide to Pharmacology lists the WHO INN CAS Registry number for cibinetide as 1208243-50-8.

Is ARA-290 the same as erythropoietin?

No. ARA-290 is derived from a tissue-protective region of erythropoietin, but it is a distinct engineered peptide with a different intended signaling profile.

Does ARA-290 stimulate red blood cell production like EPO?

The literature describes ARA-290 as a nonerythropoietic peptide designed to avoid the classical erythropoietic effects associated with erythropoietin.

Is there human research on ARA-290?

Yes, but it is still limited. Early studies in sarcoidosis-associated small fiber neuropathy and type 2 diabetes with neuropathic symptoms reported encouraging signals, but larger definitive evidence is still needed.

Scientific References

PubChem. Cibinetide (CID 91810664).
https://pubchem.ncbi.nlm.nih.gov/compound/Cibinetide
Guide to Pharmacology. Cibinetide ligand page.
https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9677
Heij L, et al. Safety and Efficacy of ARA 290 in Sarcoidosis Patients with Symptoms of Small Fiber Neuropathy: A Randomized, Double-Blind Pilot Study. Molecular Medicine. 2012.
https://pmc.ncbi.nlm.nih.gov/articles/PMC3563705/
Dahan A, et al. ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density. Molecular Medicine. 2013.
https://pubmed.ncbi.nlm.nih.gov/24136731/
Culver DA, et al. Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain. Investigative Ophthalmology & Visual Science. 2017.
https://pubmed.ncbi.nlm.nih.gov/28475703/
Brines M, et al. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Molecular Medicine. 2015.
https://pubmed.ncbi.nlm.nih.gov/25387363/
Dahan A, et al. Targeting the innate repair receptor to treat neuropathy. Current Opinion in Anaesthesiology. 2016.
https://pmc.ncbi.nlm.nih.gov/articles/PMC5741312/
Lois N, et al. A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema. Scientific Reports. 2020.
https://pmc.ncbi.nlm.nih.gov/articles/PMC7408632/
Swartjes M, et al. ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response. Journal of Pharmacology and Experimental Therapeutics. 2014.
https://pubmed.ncbi.nlm.nih.gov/24529189/
Ghassemi-Barghi N, et al. Mechanistic Approach for Protective Effect of ARA290, a Non-Hematopoietic Peptide Derived from EPO, Against Cisplatin-Induced Nephrotoxicity. 2023.
https://pubmed.ncbi.nlm.nih.gov/36085231/

Research Dosage & Administration

Note: ARA-290 is currently intended for laboratory research purposes.

Common Research Dose: Preclinical and clinical research often utilizes doses ranging from 1 mg to 8 mg per day.
Common Protocol: Subcutaneous injection is the most frequent administration route in studies involving neuropathy and metabolic health, typically for a duration of 4 to 12 weeks.
Half-Life: It has a relatively short plasma half-life (approx. 2 minutes), yet its biological effects persist much longer due to the initiation of downstream intracellular repair cascades.

ARA-290 Research Reference

Looking for a research-focused source built around transparent standards, documentation, and evidence-based peptide education?

Explore Luxara Labs’ core research resources: